PTK2, protein tyrosine kinase 2, 5747

N. diseases: 205; N. variants: 21
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.550 GeneticVariation disease UNIPROT
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.300 GeneticVariation disease UNIPROT
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE <i>FAK</i>-copy-gain may be a predictive marker for FAK inhibition therapy in breast cancer. 31480645 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE <i>FAK</i>-copy-gain may be a predictive marker for FAK inhibition therapy in breast cancer. 31480645 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.100 Biomarker disease BEFREE <i>In vitro</i> experiments showed that tyrosine phosphorylation of CSF-1R, ERK, and FAK and cell migration are differentially regulated by IL-34 and CSF-1 in breast cancer cell lines. 29796177 2018
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.100 Biomarker disease BEFREE <i>In vitro</i> experiments showed that tyrosine phosphorylation of CSF-1R, ERK, and FAK and cell migration are differentially regulated by IL-34 and CSF-1 in breast cancer cell lines. 29796177 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE 1204-1216) use elegant genetic approaches to simultaneously delete the essential autophagy gene FIP200 (FAK family-interacting protein of 200 kDa) and the signaling adaptor p62/SQSTM1 within established murine tumors, which reveals an unexpected synergism between the autophagy pathway and p62 in driving tumor growth. 24888584 2014
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE 5'-NIO inhibited the beta1 Integrin/FAK/Akt pathway which can then facilitate invasion and/or migration of cancer cells through the extracellular matrix (ECM). 21463917 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE 5'-NIO inhibited the beta1 Integrin/FAK/Akt pathway which can then facilitate invasion and/or migration of cancer cells through the extracellular matrix (ECM). 21463917 2011
CUI: C0151718
Disease: Hypocholesterolemia
Hypocholesterolemia 		0.010 PosttranslationalModification disease BEFREE Cholesterol depletion inhibited phosphorylation of Src on Y416 in the detergent-insoluble fraction followed by decreased localization of total and pY397 FAK in the detergent-insoluble fraction. 19945766 2010
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Tumors sensitive to saracatinib showed an increase in the activation of Src and FAK when compared with resistant tumors. 20682712 2010
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.600 Biomarker disease LHGDN FAK proteins were detected in all HCC cell lines. 15102689 2004
CUI: C0281361
Disease: Adenocarcinoma of pancreas
Adenocarcinoma of pancreas 		0.010 PosttranslationalModification disease BEFREE FAK gene silencing suppresses anoikis resistance in pancreatic adenocarcinoma cells. 15118593 2004
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE FAK protein overexpression in tumors correlated with nodal metastases. 16740747 2006
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.300 AlteredExpression phenotype BEFREE FAK protein overexpression in tumors correlated with nodal metastases. 16740747 2006
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm 		0.070 AlteredExpression group BEFREE FAK protein overexpression in tumors correlated with nodal metastases. 16740747 2006
CUI: C0027819
Disease: Neuroblastoma
Neuroblastoma 		0.040 AlteredExpression disease BEFREE FAK protein expression also correlated positively with N-MYC expression in the N-MYC-amplified IMR-32 versus nonamplified SK-N-AS neuroblastoma cell lines. 17327229 2007
CUI: C0700095
Disease: Central neuroblastoma
Central neuroblastoma 		0.040 AlteredExpression disease BEFREE FAK protein expression also correlated positively with N-MYC expression in the N-MYC-amplified IMR-32 versus nonamplified SK-N-AS neuroblastoma cell lines. 17327229 2007
CUI: C4086165
Disease: Childhood Neuroblastoma
Childhood Neuroblastoma 		0.040 AlteredExpression disease BEFREE FAK protein expression also correlated positively with N-MYC expression in the N-MYC-amplified IMR-32 versus nonamplified SK-N-AS neuroblastoma cell lines. 17327229 2007
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE FAK is overexpressed in human tumors and regulates cellular adhesion and survival signaling. 17849451 2008
CUI: C1519670
Disease: Tumor Angiogenesis
Tumor Angiogenesis 		0.030 Biomarker phenotype BEFREE FAK was held responsible for cancer cells' uninhibited proliferation, protection from apoptosis, invasion, migration, adhesion and spreading, as well as tumor angiogenesis. 18283648 2008
CUI: C1458155
Disease: Mammary Neoplasms
Mammary Neoplasms 		0.100 AlteredExpression group BEFREE FAK mRNA expression was also found to correlate with TP53 mutation status in a series of breast tumors. 21071137 2011
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE FAK1 is known to enhance migration of cancer cells and promote metastatic dissemination to distant sites. 21707507 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE FAK1 is known to enhance migration of cancer cells and promote metastatic dissemination to distant sites. 21707507 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE FAK and WNT signaling: the meeting of two pathways in cancer and development. 21707509 2011